What is Macimorelin (non-peptide)?
An oral ghrelin-receptor agonist approved by the FDA (Macrilen) as a one-time diagnostic test for adult growth hormone deficiency.
Macimorelin (non-peptide) in the library · · Human Trials · What are peptides?
5 registered trials · 4 indexed papers · 3 human / 0 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Macimorelin is described as an orally active peptidomimetic growth hormone secretagogue.
Evidence (as described)
- A pivotal study found it as accurate as the insulin tolerance test for diagnosing adult GH deficiency (Garcia et al., 2018). A pilot trial explored it in cancer cachexia (Herodes et al., 2023).
Status
FDA-approved (2017) as a diagnostic agent (Macrilen); approved in the EU as Ghryvelin.
Registered human trials (5)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is | Phase 3 | completed | 2021 | 101 |
| Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers | completed | 2019 | 28 | |
| Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency | Phase 3 | completed | 2015 | 157 |
| Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia | Phase 2 | completed | 2012 | 15 |
| Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test. | Phase 3 | completed | 2007 | 101 |
Peer-reviewed studies (4)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia | Herodes M et al. | Journal of cachexia, sarcopenia and muscle | 2023 | Randomized Controlled Trial |
| Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants | Lissy M et al. | Clinical pharmacology in drug development | 2021 | Randomized Controlled Trial |
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study | Klaus B et al. | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society | 2020 | Randomized Controlled Trial |
| Macimorelin as a Diagnostic Test for Adult GH Deficiency | Garcia JM et al. | The Journal of clinical endocrinology and metabolism | 2018 | Randomized Controlled Trial |
Conditions researched
Related compounds
- Anamorelin (non-peptide)
- Elagolix (non-peptide)
- Enclomiphene (non-peptide SERM)
- Insulin (regular human)
- Liraglutide
- Somatostatin
- ACE-031
- Angiotensin II
- Apelin
- BNP (Nesiritide)
FAQ
What is Macimorelin (non-peptide)?
An oral ghrelin-receptor agonist approved by the FDA (Macrilen) as a one-time diagnostic test for adult growth hormone deficiency.
How many registered human trials study Macimorelin (non-peptide)?
The PeptideWhiz trial index lists 5 registered trials for Macimorelin (non-peptide), the most recent from 2021.
How much published research exists on Macimorelin (non-peptide)?
The PeptideWhiz paper index links 4 PubMed papers to Macimorelin (non-peptide); by study type, 3 human and 0 animal studies.
Which conditions is Macimorelin (non-peptide) researched for?
Muscle gain, sarcopenia & building muscle after 40.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).